Castle Biosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.04.24	Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024 (Businesswire)
10.04.24	Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations (Businesswire)
10.04.24	Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year (Businesswire)
04.04.24	Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer (Businesswire)
02.04.24	Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (Businesswire)
25.03.24	Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year (Businesswire)
12.03.24	Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum (Businesswire)
08.03.24	Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting (Businesswire)
07.03.24	In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups (Businesswire)
28.02.24	Recap: Castle Biosciences Q4 Earnings (Benzinga)
28.02.24	Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results (Businesswire)
27.02.24	Earnings Preview For Castle Biosciences (Benzinga)
26.02.24	Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging (Businesswire)
07.02.24	Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024 (Businesswire)
14.01.24	Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii® (Businesswire)
09.01.24	Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report (Businesswire)
08.01.24	Castle Biosciences Expects FY23 Revenue To Exceed $210 Mln, Surpassing Previous Outlook (RTTNews)
20.12.23	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
01.12.23	Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results (Businesswire)
14.11.23	Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting (Businesswire)
13.11.23	Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year (Businesswire)
08.11.23	Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder (Businesswire)
08.11.23	Castle Biosciences to Present at Upcoming Investor Conferences (Businesswire)
03.11.23	Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas (Businesswire)
02.11.23	Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy (Businesswire)
01.11.23	Ausblick: Castle Biosciences stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
24.10.23	Castle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting (Businesswire)
19.10.23	Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2 (Businesswire)
18.10.23	New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference® (Businesswire)
05.10.23	DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma (Businesswire)
02.10.23	Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus (Businesswire)
25.09.23	Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma (Businesswire)
19.09.23	Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry (Businesswire)
14.09.23	TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus (Businesswire)
12.09.23	Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory (Businesswire)
08.09.23	TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus (Businesswire)
06.09.23	Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023 (Businesswire)
05.09.23	Castle Biosciences to Participate in Upcoming Investor Conferences (Businesswire)
07.08.23	New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus (Businesswire)
01.08.23	Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference (Businesswire)
01.08.23	Ausblick: Castle Biosciences veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
19.07.23	Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2 (Businesswire)
18.07.23	Castle Biosciences to Host Second Annual Castle Cares Charity Walk (Businesswire)
17.07.23	Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year (Businesswire)
07.07.23	Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer (Businesswire)
30.06.23	Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Castle Biosciences Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten